STALICLA

STALICLA has developed the first neurodevelopmental disorder-specific precision medicine discovery platform with an initial application in autism spectrum disorder (ASD). Until now, patient diagnosis and drug development for ASD and other NDDs have relied on behaviorally based disease classifications, which do not correlate with biological status and fail to acknowledge patient diversity-contributing to high rates of clinical failure. STALICLA’s DEPI technology is looking to change that by integrating clinical, genetic and molecular data to identify biologically distinct subgroups and treatments to match.